LOUVAIN-LA-NEUVE, BELGIUM, February 23, 2017 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract with Quirónsalud, Spain’s leading hospital group and part of Germany’s Helios Group, to install a Proteus®ONE* compact proton therapy solution in Madrid.
The contract covers delivery of a Proteus®ONE solution, including latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities and a long-term maintenance agreement. The hospital group will also benefit from Penn Medicine and IBA’s world leading proton therapy clinical education program. The hospital will be ready to start treating patients by 2019.
The typical end-user price for a Proteus®ONE system with a maintenance contract is between EUR 35 and 40 million. This will be IBA’s 18th installation of the compact single-room proton therapy solution.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Olivier Legrain, Chief Executive Officer of IBA, commented: “IBA’s first entry into the Spanish market demonstrates the ongoing appeal of IBA’s single room solution, Proteus®ONE. Being selected by Quirónsalud to install the first proton therapy solution in Spain, reinforces our position as the global proton therapy market leader and will bring access to the most advanced radiation therapy technology to cancer patients to this region.”
Leticia Moral Iglesias, General Director of Care, Quality and Innovation of Quirónsalud group, commented: “Our mission is to improve the health of patients and this can only be done by providing the highest quality health service. After the recent merger with Fresenius Helios, we are excited to partner with IBA to bring the world’s leading proton beam therapy equipment to cancer patients in Iberia for the first time. This innovative technology will enable us to ‘paint’ tumours with a super-fine beam of protons, destroying the cancer cells whilst limiting the exposure of healthy tissues surrounding the tumor and reducing the risk of secondary cancers. At Quirónsalud, we believe that this state-of-the-art technology will also attract patients from other countries.”
About Proteus®ONE
Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes proton therapy easy.
